These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22541416)

  • 41. Omalizumab for severe allergic asthma: 7 years and open questions.
    Solèr M
    Respiration; 2014; 88(2):158-61. PubMed ID: 24818580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omalizumab for the Treatment of Multiple Food Allergies.
    Hui Shi En E; Cheng-Chung Wei J
    N Engl J Med; 2024 May; 390(20):1936. PubMed ID: 38810197
    [No Abstract]   [Full Text] [Related]  

  • 43. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal.
    Durack A; Matin RN
    Br J Dermatol; 2014 Jul; 171(1):10-3. PubMed ID: 25066288
    [No Abstract]   [Full Text] [Related]  

  • 44. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allergic asthma and omalizumab--the experience at the Centro Hospitalar da Cova da Beira.
    Simões Saldanha Mendes M; Valente MJ; Vicente I; Magalhães E; Valente S
    Rev Port Pneumol; 2013; 19(4):186-7. PubMed ID: 23731772
    [No Abstract]   [Full Text] [Related]  

  • 46. Occupational wheat contact dermatitis and treatment with omalizumab.
    Mur Gimeno P; Martín Iglesias A; Lombardero Vega M; Bautista Martínez P; Ventura López P
    J Investig Allergol Clin Immunol; 2013; 23(4):287-8. PubMed ID: 23964563
    [No Abstract]   [Full Text] [Related]  

  • 47. Response to: 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal'.
    Rosén K; Maurer M; Hsieh H; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    Br J Dermatol; 2014 Jul; 171(1):15-6. PubMed ID: 25066290
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of omalizumab in a patient with three types of chronic urticaria.
    Vieira Dos Santos R; Locks Bidese B; Rabello de Souza J; Maurer M
    Br J Dermatol; 2014 Feb; 170(2):469-71. PubMed ID: 24102388
    [No Abstract]   [Full Text] [Related]  

  • 49. Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness.
    Paterniti MO; Breslin LM; Courneya JP; Sterba PM; Hamilton RG; MacGlashan DW; Saini SS
    J Invest Dermatol; 2014 Jun; 134(6):1743-1744. PubMed ID: 24366613
    [No Abstract]   [Full Text] [Related]  

  • 50. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab.
    Wolf BL; Johnson A
    J Allergy Clin Immunol Pract; 2014; 2(1):111-3. PubMed ID: 24565782
    [No Abstract]   [Full Text] [Related]  

  • 52. Omalizumab for the Treatment of Multiple Food Allergies. Reply.
    Wood RA; Togias A; Chinthrajah RS
    N Engl J Med; 2024 May; 390(20):1936. PubMed ID: 38810198
    [No Abstract]   [Full Text] [Related]  

  • 53. Echinococcus multilocularis infection in a patient treated with omalizumab.
    Skiepko R; Zietkowski Z; Skiepko U; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
    J Investig Allergol Clin Immunol; 2013; 23(3):199-200. PubMed ID: 23967760
    [No Abstract]   [Full Text] [Related]  

  • 54. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
    Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
    Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of exercise-induced anaphylaxis with omalizumab.
    Bray SM; Fajt ML; Petrov AA
    Ann Allergy Asthma Immunol; 2012 Oct; 109(4):281-2. PubMed ID: 23010237
    [No Abstract]   [Full Text] [Related]  

  • 56. Increase in human basophils IgE-mediated stimulation by omalizumab: a role for membrane FcγRs?
    Chirumbolo S; Olivieri M
    J Allergy Clin Immunol; 2014 May; 133(5):1493-4. PubMed ID: 24642141
    [No Abstract]   [Full Text] [Related]  

  • 57. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omalizumab treatment in severe adult atopic dermatitis.
    Thaiwat S; Sangasapaviliya A
    Asian Pac J Allergy Immunol; 2011 Dec; 29(4):357-60. PubMed ID: 22299316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.
    Tanou K; Zintzaras E; Kaditis AG
    Pediatr Pulmonol; 2014 May; 49(5):503-7. PubMed ID: 24167019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?
    Castells MC; Hornick JL; Akin C
    J Allergy Clin Immunol Pract; 2015; 3(3):350-5. PubMed ID: 25858055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.